Abstract 401P
Background
Tumour shrinkage and disease control with preservation or improvement in quality of life are the primary treatment goals for patients (pts) with unresectable mCRC.1 When not possible, emphasis lies in avoidance of rapid disease evolution, and prolonging survival.1 Advances in mCRC treatment have now improved survival to an average of 30 months in clinical trials.1 Here we present treatment patterns from 531 pts from the PROMETCO study (NCT03935763), the first international, prospective real-world study to investigate the continuum of care in the mCRC population, collecting data on all pts regardless of treatment or age.
Methods
Enrolment in PROMETCO started in March 2019. Adult pts with two disease progressions since diagnosis of metastasis, and who were suitable to receive subsequent treatment were included. A treatment line (L) was defined by the first administration of a new drug. The cut-off date for this analysis was 1 October 2021.
Results
Baseline demographics and disease characteristics were in line with those reported previously.2 Median time between diagnosis of metastases and PROMETCO inclusion was 23 months, while median total treatment duration before inclusion was 13.3 months. At inclusion, pts had prior exposure to fluoropyrimidine (98%), oxaliplatin (84%), irinotecan (88%) and anti-VEGF (75%), and 68%/23% of the pts had a previous colorectal/liver surgery, respectively. Among completed pts, in 1L, 21% received CT doublet/triplet therapy and 71% received CT doublet/triplet + anti-VEGF/EGFR; in 2L, 19% received CT doublet/triplet and 63% received CT doublet/triplet + anti-VEGF/EGFR. Eighty-one percent of the population received 3L treatment, while only 24% had 4L. In 3L and 4L, 68% and 38% received FTD/TPI and 14% and 43% received regorafenib, respectively.
Conclusions
Preliminary data from 531 pts in PROMETCO provide a greater understanding of the population and key insights into the treatments received by mCRC pts in clinical practice. In 1L and 2L, most of the pts received CT doublet/triplet + anti-VEGF/EGFR. In-depth analysis is planned to better understand the 3L and 4L treatment allocation (based on access to treatment options locally).
Clinical trial identification
NCT03935763.
Editorial acknowledgement
The authors thank Peter Stevenson, PhD, Principal Medical Writer at Prescript Communications Ltd, Hertfordshire, UK for providing medical writing support, which was funded by Servier, Suresnes, France in accordance with Good Publication Practice (GPP3) guidelines.
Legal entity responsible for the study
Servier Affaires Médicales, France.
Funding
Servier Affaires Médicales, France.
Disclosure
J. Bachet: Financial Interests, Personal, Other, Honoraria: Amgen, AstraZeneca, MSD, Pierre Fabre, Servier, Viatris; Financial Interests, Personal, Other, Honoraria and Travel / accommodation / expenses: Bayer, Merck Serono, Roche, Sanofi; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Incyte, Merck Serono, MSD, Pierre Fabre, Servier; Financial Interests, Personal, Research Grant: AstraZeneca. G.M. Bodoky: Financial Interests, Institutional, Advisory Board: Roche, Janssen, Servier, Merck, Novartis. F.E. Marti: Financial Interests, Personal, Invited Speaker: Servier; Non-Financial Interests, Principal Investigator, PI PROMETCO study: Servier. E. Choucair: Financial Interests, Personal, Full or part-time Employment: Servier. M. Fazilleau: Financial Interests, Personal, Full or part-time Employment: Servier. A. Sullivan: Financial Interests, Personal, Full or part-time Employment: Servier Pharmaceuticals. R. Garcia-Carbonero: Financial Interests, Personal, Advisory Board: AAA, Advanz Pharma, Amgen, Bayer, HMP, Ipsen, Merck, Midatech, MSD, Novartis, Pierre Fabre, Roche, Servier; Financial Interests, Institutional, Research Grant: BMS, MSD, Pfizer; Non-Financial Interests, Leadership Role, Global PI of investigator-initiated clinical trials (AXINET, NICENEC, PEMBROLA): BMS, MSD, Pfizer; Other, Other, Honoraria received by spouse for advisory board or invited speaker roles: AbbVie, AstraZeneca, Bayer, Boehringer, BMS, Genomica , Lilly, MSD, Merck, Novartis, Pfizer, Pharma Mar, Roche, Sanofi, Servier, Takeda. M. Koopman: Financial Interests, Institutional, Advisory Board, advisory board and speaker: Pierre Fabre; Financial Interests, Institutional, Advisory Board: MSD, Bayer; Financial Interests, Institutional, Advisory Board, Advisory Board, speaker: Servier; Financial Interests, Institutional, Invited Speaker: Merck, BMS, Servier; Financial Interests, Institutional, Research Grant: Servier, Roche, Bayer, Bristol Myers Squibb, Merck, Personal Genomics Diagnostics, Sirtex, Pierre Fabre; Financial Interests, Institutional, Funding: Pierre Fabre, Amgen, Nordic Farma, Novartis, Merck, Servier, BMS; Non-Financial Interests, Leadership Role, vice-chair of DCCG: Dutch Colorectal Cancer Group; Non-Financial Interests, Advisory Role, Member of KWF scientific board: KWF; Non-Financial Interests, Other, ESMO faculty member for the Gastro-Intestinal Tumours – colorectal cancer: ESMO; Non-Financial Interests, Advisory Role, expert member of committee “regie op registers dure geneesmiddelen” ZINNL: ZiNNL; Non-Financial Interests, Advisory Role, CRC expert on Kanker.nl platform for answering online CRC questions of CRC (non) patients: Patient representative organisation (Kanker.nl); Non-Financial Interests, Leadership Role, chair of RWD & DH working group: ESMO; Other, Other, PI of the Dutch Prospective Colorectal Cancer Cohort study: PLCRC project. All other authors have declared no conflicts of interest.